Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

and regulatory processes related to carfilzomib, and potential benefits of the modification of the FOCUS Phase 3 study.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to:  Onyx may never receive marketing approval for carfilzomib; failures or delays in Onyx's clinical trials;  if approved, Onyx may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib; serious adverse side effects, if they are associated with carfilzomib; competition; government regulation; and  protection of Onyx's intellectual property.  Any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.  

(i)National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures

(ii)International Agency for Research on Cancer, GLOBOCAN 2002 database


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
(Date:9/1/2015)...   Medfusion, Inc., a patient engagement ... and patients, today announced a $3 million investment ... venture capital firms.   "We welcome ... City Venture Partners and Hatteras Venture Partners," said ... Chairman. "Both firms, experience working at the intersection ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted ... Los Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer Research, ... world’s first multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... first-cycle,approval for a new molecular entity (NME) is ... average, according to a new analysis from,PAREXEL Consulting, ... PRXL ),and leading global life sciences consultancy serving ... PAREXEL Consulting,analysis, 60 percent of sales for newly-approved ...
... Medical and Security Detection Applications, ST. LOUIS, ... SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: ... the scope of its electronic materials,offering with the ... http://www.safchitech.com/halides ). These new raw materials enable the,growth ...
... ... Nutrition and Disease Research, KANNAPOLIS, N.C. ... Research Institute (DHMRI), located at the North,Carolina Research Campus ... that Waters(R) has been selected as the institute,s,primary supplier ...
Cached Biology Technology:PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 2SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 3SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 4David H. Murdock Research Institute Taps Waters for Laboratory Technology 2David H. Murdock Research Institute Taps Waters for Laboratory Technology 3
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... at the University of Leeds are developing methods of ... organic chemicals such as vinegar. , The harmful ... waste from former textiles factories, smelters, and tanneries have ... to problems with the kidneys, liver, lungs and skin. ...
... 3, 2009) When it comes to solving complex ... engineer, looks to nature for solutions. Finding inspiration in ... helping to tackle one of society,s biggest challenges: improving ... the survival rate of cancer patients. Today, ...
... March 2, 2009 Two researchers at UT ... Research Fellows, an award intended to "support the work ... and often at pivotal stages in their work." ... for their work in chemistry. The Alfred P. Sloan ...
Cached Biology News:Cleansing toxic waste -- with vinegar 2MIT student develops new innovations to selectively kill cancer cells 2MIT student develops new innovations to selectively kill cancer cells 3MIT student develops new innovations to selectively kill cancer cells 4Two UT Southwestern researchers awarded Sloan fellowships 2
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: